As of 13th March 2013, a ban was introduced in the European Union (EU) on animal testing of ingredients for cosmetics. The ban applies to all new cosmetics and their ingredients sold in the EU, regardless of where in the world testing on animals was carried out. Cosmetics Europe (formerly COLIPA), the European trade association for the cosmetic, toiletry and perfumery industry, is looking to introduce novel in-vitro assays for testing key sensitizers/allergens as a replacement for animal testing in cosmetics. This will also apply to other products including chemicals, pharmaceuticals, and household products. It means that any product within these categories will have to be tested for the presence of sensitizers. Read more
Block Admission Return... Read More.
Proteome Sciences presented four posters that revealed new data and assays in Alzheimer’s disease (AD) at the 11th Annual Conference on Alzheimer’s and Parkinson’s Disease (ADPD) in Florence, Italy. These generated considerable additional interest for PS Biomarker Services™ and included:
Through these, PS Biomarker Services™ has considerably expanded its range of novel tools and assays to test AD drugs in development and for early diagnosis in blood and CSF. The fourth poster:
provided further data confirming that our in vivo study using proprietary CK1D inhibitors improved cognitive function in AD. Using a targeted proteomics approach and a smart outsourcing strategy we were able to confirm CK1D as a candidate tau Kinase and generate a library of nearly 500 small molecule inhibitors. Our two lead compounds PS110 and PS278-05 have been taken through to in vivo proof of concept. Both compounds are orally available and well tolerated in a mouse tauopathy model. Administration of PS110 led to a significant improvement in spatial memory and to a reduction in tau phosphorylation. Read More. Or View Posters
Following the Company’s announcement on 31 December 2012(RNS: 4741U), regarding the improved cognitive function demonstrated by the Proteome’s CK1D compounds, the Board has been pleased by the strong interest it has received from pharmaceutical companies. The Board is actively pushing the CK1D programme forward with the pharmaceutical industry in order to be able to bring the compounds to clinical trials. Discussions have commenced to out license the CK1D programme as soon as possible in 2013 and the Directors expect that the novel nature of the compounds in the tau pathway should materially increase the Company’s IP asset value. Industry benchmarks indicate that these should command considerable license fees, milestones and royalties. Analysis of the 1,000 Alzheimer’s patient sample set with King’s College is on-going and further results will be announced when the data processing is completed. Read More.
Proteome Sciences is pleased to announce that the in-vivo study of its proprietary CK1D inhibitor programme in Alzheimer’s disease was completed as anticipated in December 2012.
Having already confirmed earlier in the year that CK1D inhibitors block tau phosphorylation in cell lines in an in-vitro study, Proteome Sciences is delighted to announce that both of its lead compounds for CK1D have demonstrated improved cognitive function in the current study. These results provide important in-vivo proof of principle and demonstrate the efficacy of our compounds. The next phase will start immediately in January to undertake and complete a comprehensive assessment of biological indicators and drug levels in various tissues. Read More
Block Admission Return.. Read More.
“The excellent first half performance has continued with strong news flow, product launches and activity. The number of biomarker tests available from PS Biomarker ServicesTM is set to double in 2012, with major licenses and contracts from our proprietary biomarkers and services expected to add significantly to revenues in the second half of the year." Read More
Researchers at the University of Geneva (UNIGE), in collaboration with UK company Proteome Sciences plc (PS) describe a simple blood test that could substantially increase the number of patients eligible for highly effective ischaemic stroke therapy in a landmark paper “Blood Glutathione S-Transferase-ï° (GSTP) as a Time Indicator of Stroke Onset”, published today in the journal PLoS ONE. Read More.
22 August 2012 - The Directors of Proteome Sciences have been made aware of certain speculative and inappropriate comments regarding its US biomarker patent portfolio in light of two recent US court rulings on patent eligibility. We have reviewed the outcomes of the recent U.S. Supreme Court decision on Mayo v. Prometheus and U.S. Court of Appeals for the Federal Circuit decision on Associated Molecular Pathology v. United States Patent and Trademark Office with our US patent attorneys and we conclude that these decisions do not change the status of our issued and pending U.S. applications or impacted our granted U.S. patents which all continue to remain in good standing. The Company continues to fully prosecute and enforce its extensive biomarker patent estate in all territories, including the US to derive maximum value for our shareholders. Read More
20 August 2012 - London, UK. Proteome Sciences plc (Proteome) has announced that they will collaborate with CHDI Foundation, Inc. on a systems biology project regarding Huntington’s disease. Initially, Proteome will provide its PS Biomarker Services™ protein profiling to CHDI’s research programs. The analyses will be performed at Proteome’s facility in Frankfurt am Main (Germany), which is certified according to the international quality standards of ISO 9001:2008. Read More.
Proteome Sciences has achieved further milestones in the development of inhibitors of the casein kinase 1 delta (CK1d) target in its Alzheimer's disease portfolio. A second round of structure activity relationship (SAR) modelling of the most active and selective CK1d inhibitors has produced a marked improvement in activity and selectivity against the main anti-target. Read More
We delivered strong growth in 2011 and are seeing significant like for like growth in the first half of 2012 and most encouragingly with a much greater contribution expected to come in the second half of the year. Read More.
Posting of Reports and Accounts.. Read More.
2011's Annual Report. Click Here.
Considerable progress was made in each of the three main business divisions proprietary biomarkers, biomarker services and reagents. Contracts were announced with Eisai, Takeda and Siena Biotech, collaborations with The Moffitt Cancer Center and The Buck Institute in the US in the fields of cancer pathways and breast cancer respectively and further EU framework 7 grant funding through DENAMIC (Developmental Neurotoxicity Assessment of Mixtures in Children). These will enable us to rapidly produce novel biomarker assays and expand our range of products and sales. Read More.
In accordance with the FSA's Disclosure and Transparency Rule 5.6.1, Proteome Sciences plc (the "Company") announces that the Company's issued share capital consists of 192,498,477 ordinary shares of 1 pence each ("Ordinary Shares") with voting rights. There are no Ordinary Shares held in treasury.
Therefore the total number of voting rights in Proteome Sciences plc at the date of this notice is 192,498,477. Read More
Proteome Sciences plc, a global leader in protein biomarkers has today granted a non-exclusive license to Randox Laboratories (“Randox”) of Crumlin, UK for its portfolio of stroke biomarkers. Read More.
Proteome Sciences plc Block Admission Report. Read More
28 March 2012, London, UK - Proteome Sciences, in collaboration with the National Institute for Health Research (NIHR) Biomedical Research Centre for Mental Health and Merck Millipore, today announces the completion of the large, 1,000 sample Alzheimer’s Disease (AD) biomarker validation study. Preliminary results indicate that these biomarkers have significant potential diagnostic and prognostic utility that could form the basis of a series of simple blood tests for the diagnosis and management of this debilitating disease. Read More.
19th March 2012 Proteome Sciences plc (“Proteome Sciences”) announces that Euro-HYP-1, a consortium of leading academic, clinical and industrial European partners in which it is a member, has been awarded a near €11m grant under the EU Framework 7 programme for new ground breaking research on the treatment of stroke. Read More
The Company has been informed that Cubana Investments Limited (“Cubana”) has been acquired by Vulpes Life Science Fund (“Vulpes). Following this transaction, and as of 9 March 2012, Cubana no longer has a voting interest in the Company and Vulpes has voting control over 33,100,000 ordinary shares in the Company representing 17.19% of the Company’s voting share capital. Read More
The Company announces the appointment of Cenkos Securities plc, as Nominated Adviser and Broker to the Company, with immediate effect. Read More
Proteome Sciences plc (“Proteome”) announces that on 24 February 2012 it made an award of options over 328,105 Ordinary Shares of 1 pence each with an exercise price of 1 pence per share to Christopher Pearce, Chief Executive Officer under the 2011 Long Term Incentive Plan (the “LTIP”) . Read More
Proteome Sciences plc (the “Company”) announces that the Company’s issued share capital consists of 192,448,477 ordinary shares of 1 pence each (“Ordinary Shares”) with voting rights. There are no Ordinary Shares held in treasury. Read More
Proteome Sciences announces that application has been made to AIM, a market of the London Stock Exchange plc, for the admission of 176,069 ordinary shares of 1p each (the "New Ordinary Shares"). Read More
Further to comments in the Interim Statement of 30th September, 2011 regarding CK1δ (the candidate drug target for Alzheimer’s Disease), Proteome Sciences is pleased to announce that selected compounds, previously identified as potential inhibitors against CK1δ, have now been tested in cells and have shown strong activity. Further IP has been filed to cover the results which the Directors believe will considerably increase the value of the CK1δ programme. Read More
Proteome Sciences today announces that it has developed a number of novel invitro tests for chemical compounds and substances that induce allergies when they come into contact with the skin or the respiratory system. Testing for these allergens in products including chemicals, pharmaceuticals, cosmetics and detergents will become mandatory under EU legislation. Read more
November 2011 Proteome Sciences plc (“Proteome”) is pleased to announce that on 7 November it granted options under its 2011 Long Term Incentive Plan to certain directors. Read more.
Proteome Sciences plc block admission return. Read more
PS Announces half yearly statement. Read More
Proteome Sciences plc (“Proteome”) is pleased to announce that it has entered into a Master Research Agreement (MRA) with Siena Biotech S.p.A. (“Siena Biotech”) under which it has been retained as preferred supplier of protein and peptide biomarker services for Siena’s drug development programs. Read More
Proteome Sciences is pleased to announce the appointment of Glenn Barney as VP Business Development in North America. He brings over 25 years of experience with global pharmaceutical companies and the life science industry with extensive operations and business development expertise including building and managing global sales, service and product support teams and overseeing multiple product launches. Read More
Proteome Sciences plc (“Proteome”) a global leader in biomarkers will collaborate with Buck Institute for Research on Aging (“Buck”) to develop personalized molecular tests for estrogen receptor alpha (ERa) aimed at improving outcomes in breast cancer. Read More
Proteome Sciences plc (“Proteome”) a global leader in applied proteomics has entered into a collaboration agreement with Moffitt Cancer Center (“Moffitt”). Under the agreement, Proteome will support research to develop mass spectrometry assays measuring certain key signalling and repair pathway proteins that can be adapted for tumour biopsy analysis in the clinic. Read More
Proteome Sciences plc (“Proteome Sciences”) announces that it is a participant in a new project, that has been awarded a €6.99m EU Framework 7 Grant over the next two years to study the effects of environmental contamination in health and developmental disorders in children. Proteome Sciences will receive €530,058 for its contribution to the project. Read More
With the already considerable and growing portfolio of highly developed biomarkers, biomarker assays and the state of the art protein biomarker CRO capability Proteome Sciences now has under its belt, combined with a major increase in marketing and business development, the Board is most confident of achieving significant growth in revenues in the year ahead and beyond. Read More
Proteome Sciences plc (“Proteome”) is pleased to announce that Takeda Pharmaceutical Company Limited (“Takeda”) has signed a further contract to use PS Biomarker Services™. PS Biomarker Services™ will provide Takeda with mass spectrometric assays for disease related proteins. Read More
